JP2013523680A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523680A5
JP2013523680A5 JP2013501789A JP2013501789A JP2013523680A5 JP 2013523680 A5 JP2013523680 A5 JP 2013523680A5 JP 2013501789 A JP2013501789 A JP 2013501789A JP 2013501789 A JP2013501789 A JP 2013501789A JP 2013523680 A5 JP2013523680 A5 JP 2013523680A5
Authority
JP
Japan
Prior art keywords
cancer
amino
trifluoromethyl
hydroxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501789A
Other languages
English (en)
Japanese (ja)
Other versions
JP5816259B2 (ja
JP2013523680A (ja
Filing date
Publication date
Priority claimed from DE102010014426A external-priority patent/DE102010014426A1/de
Application filed filed Critical
Publication of JP2013523680A publication Critical patent/JP2013523680A/ja
Publication of JP2013523680A5 publication Critical patent/JP2013523680A5/ja
Application granted granted Critical
Publication of JP5816259B2 publication Critical patent/JP5816259B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501789A 2010-04-01 2011-03-28 腫瘍治療用の新規なpan−CDK阻害剤の使用 Expired - Fee Related JP5816259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010014426A DE102010014426A1 (de) 2010-04-01 2010-04-01 Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014426.6 2010-04-01
PCT/EP2011/054733 WO2011120922A1 (de) 2010-04-01 2011-03-28 Verwendung neuer pan-cdk-inhibitoren zur behandlung von tumoren

Publications (3)

Publication Number Publication Date
JP2013523680A JP2013523680A (ja) 2013-06-17
JP2013523680A5 true JP2013523680A5 (enExample) 2014-05-15
JP5816259B2 JP5816259B2 (ja) 2015-11-18

Family

ID=43858236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501789A Expired - Fee Related JP5816259B2 (ja) 2010-04-01 2011-03-28 腫瘍治療用の新規なpan−CDK阻害剤の使用

Country Status (21)

Country Link
US (1) US20130210846A1 (enExample)
EP (1) EP2552450A1 (enExample)
JP (1) JP5816259B2 (enExample)
KR (1) KR20130014678A (enExample)
CN (1) CN102834100A (enExample)
AU (1) AU2011234654B2 (enExample)
BR (1) BR112012024422A2 (enExample)
CA (1) CA2794996A1 (enExample)
CL (1) CL2012002753A1 (enExample)
CR (1) CR20120502A (enExample)
DE (1) DE102010014426A1 (enExample)
DO (1) DOP2012000260A (enExample)
EC (1) ECSP12012198A (enExample)
MA (1) MA34098B1 (enExample)
MX (1) MX337722B (enExample)
NZ (1) NZ602710A (enExample)
PH (1) PH12012501945A1 (enExample)
SG (2) SG183925A1 (enExample)
TN (1) TN2012000469A1 (enExample)
UA (1) UA108494C2 (enExample)
WO (1) WO2011120922A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140135215A (ko) * 2012-03-21 2014-11-25 바이엘 인텔렉쳐 프로퍼티 게엠베하 특정한 종양의 치료를 위한 (rs)-s-시클로프로필-s-(4-{[4-{[(1r, 2r)-2-히드록시-1-메틸프로필]옥시}-5-(트리플루오로메틸)피리미딘-2-일]아미노}페닐)술폭시미드의 용도
US20160045496A1 (en) * 2013-03-07 2016-02-18 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours
ES2734568T3 (es) * 2013-03-13 2019-12-10 Oncoceutics Inc 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
EP3010902A1 (en) * 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
WO2015071231A1 (de) * 2013-11-14 2015-05-21 Bayer Pharma Aktiengesellschaft Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
IL303237A (en) * 2020-11-27 2023-07-01 Anrui Biomedical Tech Guangzhou Co Ltd Aminoheteroaryl kinase inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
ES2253821T3 (es) 1997-07-12 2006-06-01 Cancer Research Technology Limited Derivados de purina inhibidores de quinasa que depende de ciclina.
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ES2270612T3 (es) 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP1878726A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2179991A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Similar Documents

Publication Publication Date Title
JP2013523680A5 (enExample)
JP2015512943A5 (enExample)
JP2012153722A5 (enExample)
JP2011509949A5 (enExample)
DOP2019000022A (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
JP2017511321A5 (enExample)
JP2013522292A5 (enExample)
JP2017528475A5 (enExample)
FI3636649T3 (fi) Diaryylimakrosyklejä proteiinikinaasien modulaattoreina
JP2014521625A5 (enExample)
EP4335511A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
JP2016522266A5 (enExample)
JP2016538344A5 (enExample)
JP2013539795A5 (enExample)
JP2017525730A5 (enExample)
JP2019520343A5 (enExample)
JP2013535491A5 (enExample)
JP2011527666A5 (enExample)
JP2013520443A5 (enExample)
JP2022071077A5 (enExample)
JP2017530171A5 (enExample)
MX2012013274A (es) Novedosos derivados de la pirimidina.
JP2014534269A5 (enExample)
CN113366008A (zh) 一种cd73抑制剂,其制备方法和应用
JP2019534865A5 (enExample)